Here, free fatty acid–induced release of insulin, incretins, and satiety-regulating hormones have focused attention on the potential of synthetic agonists of one or both of these receptors to provide novel approaches to regulate glycaemia and to treat metabolic disorders, such as type II diabetes (4, 6, –8); however, as with most other GPCRs, both GPR40 and GPR120 are thought to be expressed more broadly. Here, INS is linked to type 2 diabetes mellitus.